Introduction
Prevalence of hypertension (HTN) continues to rise and HTN accounts for the largest proportion of attributable cardiovascular (CV) mortality worldwide. 1 ,2 Yet CV risk substantially varies among patients with HTN, and current European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines recommend risk stratification in all patients with HTN to allow categorization into four groups of patients from low to very high CV risk. 1 Information on the level of risk of CV events may assist the identification of the threshold for initiation of treatment and target blood pressure (BP) to reach. This possibility, reinforced by the recent SPRINT and HOPE 3 data, 3, 4 may be useful in the choice of initial treatment strategy (e.g. possible initial use of combination treatment) and may orient on the need for associated treatment (e.g. antiplatelet and lipid-lowering treatment). Subclinical, i.e. asymptomatic involvement of different organs represents a key pathophysiological step along the continuum between HTN as risk factor and its impact on clinical outcome, being an independent determinant of CV risk. Thus, to further reclassify patients, especially those at moderate CV risk from SCORE risk charts, ESH/ESC guidelines recommend the assessment of subclinical target organ damage (TOD) at different organ levels ( Table 1) , as it has been reported that TOD independently predicts CV outcomes and that multi-organ TOD carries a greater risk compared with single TOD 5, 6 ( Figure 1 ). In addition, evidence of TOD may help to make the choice of the appropriate therapeutic pharmacological strategy in HTN patients. To this purpose, non-invasive CV imaging is increasingly being used and continues to provide new technological opportunities to assess TOD at increasingly early stage. In this context, information obtained from imaging techniques may be considered as risk modifiers to improve CV risk prediction and decision making. 7 Yet as addressed in HTN guidelines, 1 much uncertainty remains on the overall clinical value of TOD assessment. In fact, the independent prognostic value of therapy-induced changes of TOD, assessed by imaging parameters, is still not definitively established mainly due to the retrospective nature of available evidence. The purpose of the present document is to provide a joint opinion on behalf of the ESC European Association of Cardiovascular Imaging (EACVI), the ESH and the ESC Council on Hypertension that summarizes indications and gaps on the appropriate and justified use of CV imaging, in order to assess TOD in HTN patients, based on pathophysiological, clinical, and technical characteristics, as well as on strengths and limitations of each imaging modality.
Identification of TOD using non-invasive CV imaging
The identification of TOD through the use of CV imaging in hypertensive patients starts with a baseline evaluation that includes 12-lead electrocardiogram (ECG), renal function and urinary protein assessment, and transthoracic echocardiography. Then, it continues with an advanced evaluation, including all the other components of the CV system, as illustrated in Figure 2 and subsequently reported.
Heart
Echocardiography represents the first and most used imaging technique to assess TOD at the cardiac level. Standard echocardiography is currently used to measure left ventricular (LV) wall thickness and internal chamber diameters to quantify LV mass, determine left atrial (LA) size, and indexes of LV diastolic function. Limitations of standard echocardiography in quantifying LV mass and geometry are recognized, since it relies on geometric assumptions and has suboptimal reproducibility. In particular, this disadvantage may be problematic in obtaining accurate information on LV mass changes in individual patients over time. 8 Echo Doppler measurements of LA size and diastolic function have lower variability. 8 In general, however, the clinical use of all echo Doppler parameters of cardiac damage in arterial HTN can be somewhat limited by the fact that they are influenced by physiologic and demographic factors including age, gender, and ethnicity. 9 Cardiac magnetic resonance imaging (MRI) offers very high spatial resolution and tissue contrast and is considered the gold standard technique for measurement of cardiac function. However, reduced availability, higher costs than echocardiography, patients' claustrophobia (about 10% of all cases), and other specific cardiovascular magnetic resonance-related contraindications still limit MRI use in clinical practice. 10 
LV mass and geometry
The identification of cardiac organ damage in arterial HTN corresponds traditionally to the identification of LV hypertrophy (LVH) ; or LVM/height 2.7 : men > 50 g/m 2.7 ; women > 47 g/m 2.7 , especially when overweight is present. 
and concentric geometry, which are both caused by increased LV stress due to chronic pressure overload and represent independent hallmarks of CV risk. 1, 11, 12 Despite some controversial opinions, 13 echocardiography is in general considered to be more accurate than electrocardiogram in diagnosing LVH. 14, 15 Linear measurements of septal and posterior wall thickness and LV internal end-diastolic diameter (by M-mode or direct 2D parasternal long-axis view) allow to calculate LV mass using the Devereux cube formula, where LV
6, where IVS = interventricular septal thickness, LVID = left ventricular internal diameter, and PWT = posterior wall thickness 16 ( Figure 3) . LV mass is commonly normalized for body surface area, but this normalization makes impossible to predict LV mass in individuals who deviate from normal body weight, in particular in overweight/obese individuals. 17 The normalization for body height, a good surrogate of fat-free mass, appears to be more acceptable. However, as the relation between LV mass (a 3D variable generated by a cubic function) and height (a linear measure) cannot be linear, 18 normalizations of LV mass for height powered to 2.7 (ref. 18 ) and to 1.7 (in relation with possible influence of gender) have been proposed. 19 Yet the optimal LV mass indexation remains a controversial issue 19 , although the 2.7 power has more consolidated evidence, derived from several studies by different research groups. Relative wall thickness (RWTd = 2 Â posterior wall thickness/LV end-diastolic diameter) categorizes LV geometry (concentric or eccentric), being expression of wall to radius ratio. By combining LV mass and RWTd, concentric LVH (RWTd > _ 0.43 þ increased LV mass), eccentric LVH (RWTd < 0.43 þ increased LV mass) and concentric remodelling (RWTd > _ 0.43 þ normal LV mass) can be differentiated from normal LV geometry (RWTd < 0.43 and normal LV mass). Because of a suboptimal categorization of dilated ventricles, a novel classification, based on LV mass, LV volume, and RWTd or LV mass/volume ratio, has been proposed. 20 Using this approach, four distinct patterns, non-dilated ventricles (normal LV mass and RWTd), concentric remodelling or concentric LVH, (RWTd > _ 0.43 þ normal or increased LV mass), eccentric remodelling (RWTd < 0.43) and eccentric LVH (RWT < 0.43 þ increased LV mass) can be identified, each with distinct functional and prognostic value. 20 According to Laplace's low, the first LV wall that becomes hypertrophic is the interventricular septum. Sometimes only the basal septum is hypertrophic, since the longitudinal fibres of the basal septum have some of the largest radii among human heart fibres, thus experiencing the ). The proposed diagnostic algorithm identifies two steps in the diagnostic evaluation of subclinical TOD in hypertensive patients: a baseline assessment (STEP 1), necessary in all hypertensive patients that includes ECG assessment, evaluation of renal function, and the presence of urinary protein excretion and transthoracic echocardiography (or MRI when echocardiography is technically not feasible); an advanced assessment (STEP 2) to be considered in the presence of specific conditions that includes an integrated approach to all components of the CV system. a To be considered also if imaging of delayed enhancement would have therapeutic consequences; b depending on costs and availability should be considered in all hypertensive patients, necessary in elderly and long-standing HTN; c examination of the retina is not recommended in mild-to-moderate hypertensive patients without diabetes, except in young patients. TOD, target organ damage; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; CAD, coronary artery disease; PWV, pulse wave velocity; HTN, hypertension.
greatest inward component of wall stress. Moreover, the basal septum is the last part of the ventricle to be electrically activated, suffering from a further increase in wall stress due to the contraction of the other LV segments. 21 Great progresses have been obtained using real-time 3D echocardiography that provides very accurate estimation of LV mass and of LV mass/volume ratio, an index of concentric geometry primarily utilized by cardiac MRI. The calculation of LV mass by real-time 3D echocardiography has the advantage to do not rely on geometric formulas for calculating LV myocardial volume but measuring it directly. This allows a better accuracy and reproducibility in comparison with standard echocardiography. 22 Three-dimensional-derived LV mass has been successfully validated with cardiac MRI, and three studies (on 390, 410, and 226 subjects, respectively) reported reference normal values for 3D LV mass, which also included multiple ethnic groups (American, Japanese, and European). [23] [24] [25] However, American Society of Echocardiography (ASE)/EACVI do not recommend the clinical use of normal reference values of 3D LV mass, because little information is available on its feasibility and prognostic value in large population sample size. 26 Moreover, 3D echocardiography is not widely used in clinical practice and still remains a research tool. The better cardiac MRI reproducibility in comparison with echocardiography means that a population sample size to detect a meaningful change in LV mass can be substantially lowered (by over 80%), 27, 28 allowing for a considerable reduction in duration and cost savings of clinical trials assessing LVH regression. 29 LV diastolic dysfunction During early, mild HTN, LVH is usually absent, and the first manifestation of cardiac organ damage may be LV diastolic dysfunction (LVDD) that is currently assessed by echo Doppler examination ( Figure 4) . Using echo Doppler, LVDD can be detected as a transmitral inflow pattern of LV abnormal relaxation (E/A ratio < 1 and prolonged E velocity deceleration time). 30 However, over time and in parallel with LVH development, LV filling pressures (LVFP) can rise as an adaptive response to pressure overload and, before the onset of LV chamber systolic dysfunction, induce symptoms/signs of heart failure [heart failure with preserved ejection fraction (EF), HFpEF]. 31 Under these circumstances, the simple transmitral pattern is not sufficient to diagnose the clinical status but should be combined with further manoeuvres (Valsalva) or additional Doppler parameters (pulsed tissue Doppler of mitral annulus and estimated pulmonary pressures by measuring the degree of tricuspid regurgitation by 2continuous wave Doppler) to detect LVFP increase 30 ( Figure 5 ). velocity is an acceptable marker of myocardial relaxation and E/e 0 ratio is less dependent on ageing than other diastolic parameters. 30 Thus, this methodology should be applied to identify abnormally elevated LVFP also in the hypertensive clinical setting. Cardiac MRI is not routinely used for the detection of LVDD and requires a 'cumbersome analysis'. However, due to its non-invasive tissue characterization ability by late gadolinium contrast agent, which accumulates in extracellular matrix areas of cell death or increased interstitial space, late gadolinium enhancement (LGE)-cardiac MRI allows detection of myocardial fibrosis. 33 LGE, indicating myocardial fibrosis, is detectable in about half of the hypertensive patients, but LVDD can be present also in patients without LGE. 34 Moreover, T1
mapping, a novel developing parametric cardiac MRI technique that measures relaxation of tissues, appears more sensitive to detect myocardial fibrosis. 35 T1 mapping estimation of extracellular volume has recently shown greater diffuse fibrosis in hypertensive patients with LVH compared with non-LVH hypertensives and control subjects. 36 It is worthy to note that LVDD can be detected in many hypertensive patients without LV concentric geometry 37 and that increased noninvasively estimated LVFP (i.e. high E/e 0 ratio) is well correlated with
LGE-cardiac MRI extent of myocardial fibrosis in the absence of evident LVH. 38 The advanced speckle-tracking echocardiography can also offer functional markers of myocardial fibrosis, since serum tissue inhibitor of matrix metalloproteinases correlates with both impaired longitudinal strain rate and LV twisting 39 and circulating biomarkers of collagen turnover are inversely correlated with LV twisting 40 and radial strain 41 in hypertensive patients with normal EF. These findings strongly suggest that alteration in collagen turnover due to myocardial fibrosis Figure 4 Diagnostic algorithm for diagnosis and grading of diastolic dysfunction (Ref.
30
). The assessment of diastolic dysfunction consists of two steps: diagnosis of LV diastolic dysfunction (STEP 1) and subsequent grading of LV diastolic dysfunction (STEP 2). 30 In fact, in HTN patients with suspected HFpEF and increased natriuretic peptide levels, the presence of LA enlargement may confirm the diagnosis, according to the ESC guidelines on acute and chronic heart failure. 42 LV systolic function EF at rest may not identify subclinical systolic dysfunction in patients with HTN, and echocardiographic measurement of EF is subjected to substantial intra-and inter-observer variability compared with cardiac MRI. 10 To assess the systolic function, midwall fractional shortening, an estimate of myocardial mechanics of circumferential midwall fibres, obtainable by mathematical model from linear measures of LV cavity size and wall thickness at end-diastole and end-systole, has been proposed. 43 However, this measurement is quite complex and not widely used in clinical practice. The newly developed 3D speckletracking echocardiography represents a valuable tool for the detection of HTN-related subclinical systolic dysfunction and allows estimation of different directional strain components in the beating heart. Speckle-tracking echocardiography abnormalities of LV longitudinal, circumferential, and radial strain, as well as twisting, have been largely reported in uncomplicated hypertensive patients. However, due to its very high feasibility and excellent reproducibility, 44 the quantification of global longitudinal strain (GLS), 45 i.e. the relative LV length change between end-diastole and end-systole, should be preferred in this clinical setting ( Figure 6 ). GLS has been standardized in absolute values, and normal reference values of GLS have been identified (>20%). 16 ,45 GLS also showed 
superiority in comparison with EF to characterize LV systolic dysfunction in a population of patients with HFpEF with a large proportion of arterial HTN. 46 Moreover, GLS is able to unmask early subclinical systolic dysfunction of newly diagnosed hypertensives without LVH, 47 even in pre-hypertensive stages 48 when EF and other strain components are still normal. Thus, GLS measurement can detect asymptomatic subclinical LV dysfunction in hypertensive 49 patients, although its routine clinical application may be in part limited by the inter-vendor variability of its measurements. 44 An additional parameter, global area strain, has also been proposed, comprehensive of both subendocardial and midwall function and potentially suitable to identify early cardiac organ damage in hypertensive heart. 50 However, 3D speckle-tracking echocardiography has been studied in populations of limited sample size. It represents, therefore, a research technique, currently far from routinely clinical use.
To assess LV function, and specifically to measure LV EF, cardiac MRI provides better accuracy and reproducibility compared with echocardiography and should be preferentially used in patients with poor acoustic window. 10 Myocardial ischaemia ESC guidelines, among indications for TOD search, recommend the search for myocardial ischaemia in hypertensive patients with suspected history of coronary artery disease. Diagnosis of myocardial ischaemia in hypertensive patients is particularly challenging because HTN substantially lowers the specificity of exercise ECG and perfusion scintigraphy. 51, 52 When exercise ECG is either uninterpretable or ambiguous, an imaging test of inducible ischaemia such as perfusion scintigraphy, 53 stress echocardiography, 54 or stress cardiac MRI 55 is warranted. Among the imaging tests, stress echo has been shown to have higher specificity but reduced sensitivity compared with single-photon emission computed tomography perfusion imaging. 56 In fact, stress-induced wall motion abnormalities are highly specific for detecting epicardial coronary artery stenosis angiographically, whereas myocardial perfusion abnormalities are frequently detected in hypertensive patients with normal coronary arteries and coronary microvascular disease angiographically . 1, 10 Use of dual echo imaging of regional wall motion and coronary flow reserve (CFR) (normal values > 2) on left anterior descending artery to distinguish epicardial coronary stenosis (reduced CFR þ inducible wall motion abnormalities) from isolated coronary microcirculatory dysfunction (reduced CFR without wall motion abnormalities) has been proposed, 54 but this approach substantially prolongs acquisition time and needs validation in large clinical series. In addition, CFR measurement is not routinely performed in clinical practice. Stress cardiac MRI is a valuable option to assess myocardial ischaemia in HTN patients and should be considered when stress echocardiography is expected to be suboptimal due to technical limitations.
57 Table 2 summarizes the main echocardiographic parameters (with respective cut-off points) to characterize cardiac damage in the hypertensive heart.
Cardiovascular system Vessels
The presence of vascular damage at subclinical, asymptomatic stages can identify a 'vulnerable' patient and help to improve prevention strategies. Increased intima-media thickness (IMT) of the common carotid artery (normal value < 0.9 mm), easily measurable by vascular ultrasound, is a well-known marker of hypertension-induced vascular damage, whereas the presence of plaque can be identified by an IMT > _ 1.5 mm or by a focal thickness increase of 0.5 mm or 50% of surrounding carotid IMT value. 1 However, lack of standardization regarding the definition and measurement of IMT, its high variability and low intra-individual reproducibility have raised concerns regarding its clinical value. Arterial stiffness (AS) is one of the earliest detectable adverse structural and functional modifications of the vessel walls. AS results from a degenerative process affecting mainly the extracellular matrix of elastic arteries and is mainly influenced by ageing and risk factors, particularly arterial HTN. 58 Moreover, arterial distensibility may be further impaired by functional factors, as observed in hypertensive current and ex-smokers. 59 Changes in extracellular matrix proteins and in vascular mechanical properties may activate several mechanisms also involved in the atherosclerotic process. Non-invasive methods to estimate large vessel AS include carotid-femoral pulse wave velocity (PWV), the reference for aortic stiffness estimate that can be determined as the time delay derived from either pressure (tonometry) or ultrasound (pulsed Doppler) techniques, and local distensibility measures of superficial arteries such as carotid and femoral. 58 Measures of AS, such as aortic distensibility and PWV, can also be evaluated by phase-contrast MRI. 60 A meta-analysis showed that AS predicts CV events and improves risk classification. However, the value of this conclusion was offset by evidence of substantial publication bias. 61 Abnormal vasoreactivity due to endothelial dysfunction is commonly observed in hypertensive patients, in whom it contributes, together with arteriolar remodelling, to microvascular dysfunction. 62 Vascular endothelial-derived nitric oxide function can be assessed either in the peripheral arteries by flow-mediated vasodilation 63 or in coronary vessels by vasodilator changes of CFR. 54 Several studies investigated markers of vascular disease in arterial HTN by ultrasound, whereas more data are needed to establish the clinical value of MRI for the evaluation of vessel damage in HTN. However, independently on the technique used, the clinical value of endothelial function assessment in hypertensive patients is not established and, therefore, endothelial function assessment should not be a routine part of TOD assessment in HTN. Elevated BP has been also associated with increased aortic wall thickness, aortic diameters, and plaque extent in both thoracic and abdominal aorta. 20 HTN-induced aortic root dilation predicts subsequent development of aortic regurgitation. 64 In severe and long-standing hypertensive patients, due to increased afterload, the screening of abdominal aorta aneurysms (AAAs) by vascular ultrasound should be mandatory. AAAs are mostly silent and approximately 80% occurs in the infrarenal abdominal aorta. Most are caused by a degenerative process in the aortic wall and smoking is the concomitant risk factor most strongly associated with AAA. The detection of a pulsatile abdominal mass during systematic palpation of the abdomen has a poor sensitivity, whereas ultrasonography is an optimal tool for screening and follow-up, with low costs and no risk. According to the ESC guidelines on aortic disease, 65 diameter measurements with ultrasounds should be performed in the plane perpendicular to the arterial axis, to avoid any overestimation of the true diameter.
Coronary artery calcium
Coronary artery calcium can be detected through multi-slice computed tomography and identifies subclinical coronary atherosclerosis. However, it must be emphasized that the absence of coronary artery calcifications does not exclude atherosclerosis and that the presence of calcium does not correlate with the instability of the atherosclerotic lesions. Prevalence and severity of coronary calcium are higher in patients affected by HTN compared with normotensive subjects. 66 In fact, high BP and its duration promotes coronary calcium accumulation, in parallel with peripheral atherosclerosis. 67 
Kidney
The evaluation of TOD at the kidney level is commonly obtained by the estimation of glomerular filtration rate (eGFR) and microalbuminuria in all hypertensive patients. Nuclear imaging techniques, i.e. renal sequential scintigraphy, can be used to assess renal function, whereas MRI is able to evaluate the gross morphology of the kidneys and renal arteries, enabling planning of renal denervation and identifying renal artery stenosis as a secondary cause of arterial HTN. However, none of them is currently recommended to assess subclinical kidney damage in hypertensive patients. 1 MRI T1 relaxation time to assess parenchymal structure 68 and MRI arterial spin labelling to measure renal tissue perfusion 69 are new promising techniques that may complement in the future the standard assessment of TOD at the kidney level.
Brain HTN is associated with neurological deterioration, cognitive impairment and depression in the elderly patients. This association appears to be mediated in part by cerebral microvascular disease that is commonly detected by MRI (up to 40% of patients) in the form of lacunar infarcts (10% to 30% of patients) and white matter hyperintensities. These latter are seen in almost all elderly hypertensive patients and are predicted by the severity and duration of HTN. 70 for the development of other retinal vascular diseases, such as retinal vein and artery occlusion, and ischaemic optic neuropathy. 73 The classification of hypertensive retinopathy is based on fundoscopy and Grade III (retinal haemorrhages, microaneurysms, hard exudates, and cotton wool spots) and Grade IV retinopathy (Grade III signs and papilloedema and/or macular edema) are indicative of a severe form of retinopathy that predicts mortality. 74 Hypertension is known to be associated with an increase in the wall-to-lumen ratio of retinal arterioles. 75 Interestingly, it has been demonstrated that retinal arterioles wall-to-lumen ratio assessed non-invasively by scanning laser Doppler flowmetry is closely related to the media-to-lumen ratio measured with myography in vitro that allows an invasive evaluation of the microvasculature, demonstrating that changes of the retinal arterioles mirror those of subcutaneous small arteries. 76 Prognostic implications for imaging-detected TOD
As reported by Devereux and Alderman about 20 years ago, 77 presence of TOD attributable to HTN is a sign of "preclinical CV disease" (Figure 1 ) and can be considered as a bridge between exposure to CV risk factors and occurrence of CV events.
Heart
Cardiac morphologic adaptation LV mass is a predictor of adverse outcome in arterial HTN beyond SCORE prediction, evidence that has been produced with conventional standard 2D echocardiography and confirmed with more accurate technologies. 78, 79 In 2009, an appraisal document of the ESH reported evidence indicating that LVH is associated with a risk of CV events exceeding 20% in 10 years, thus identifying patients at high CV risk. 80 The integrated evaluation of LV mass and LV geometry is useful to understand the surrounding haemodynamic pattern, but its utility in terms of improving risk profiling remains uncertain, because the progressively increasing severity of the different LV geometric patterns parallels a corresponding increase in LV mass. 78, 79, 81 Thus, the assessment of echocardiographic LVH may assist risk stratification beyond conventional risk assessment, mostly in patients with intermediate SCORE risk. 6, 80, 82 The recent recommendations of EACVI and ASE on the use of echocardiography in adult HTN 21 report a range of definitions of LVH from mild-to-severe degree that would theoretically allow graduating risk prediction, though there is no evidence that this stratification helps risk assessment, compared with a clear-cut definition of LVH. 78 LA dimension, assessed as anteroposterior diameter, 83 or, better, as LA volume, is an additional prognosticator of CV events. 84 However, because of the close dependence of LA size from diastolic function and the correlation with LV mass, the independence of its prognostic impact remains uncertain. 83 
LV systolic function
The dependency of EF on LV geometry limits its value for the prediction of CV risk in hypertensive patients, especially in those exhibiting LV concentric geometry. 84 Midwall shortening is an LV geometryindependent estimate of wall mechanics and is significantly associated with adverse CV events. 85, 86 GLS was associated with hospitalization for HF in the TOPCAT trial, 87 a cohort with a very high prevalence of arterial HTN, yet its prognostic value for routine clinical use remains currently undefined. A very recent study has also observed that GLS deterioration is associated with major adverse cardiac events in asymptomatic hypertensive patients, a finding that warrants to assess in future studies the incorporation of GLS for predicting CV risk in hypertensive heart disease. 88 LV diastolic function LA dimension is an accurate marker of chronic diastolic dysfunction and can be used also as a prognosticator of diastolic function, in the absence of mitral valve functional abnormalities. 89 The E/A ratio is associated with adverse CV events, 90 and so is LA systolic force, 91 but the associations are not linear. Low or high values (documenting prolonged LV relaxation or increased late LV stiffness) predict
Key messages: Identification of TOD using non-invasive CV imagingcardiovascular system
• Ultrasound examination of carotid arteries is recommended to assess:
• carotid 'IMT' (normal value <0.9 mm) as an early marker of vessel damage
• 'carotid plaque' identified by an IMT > _ 1.5 mm or by a focal thickness increase of 0.5 mm or 50% of surrounding carotid IMT value
• HTN is associated with frequent asymptomatic brain damage and 'brain imaging by MRI should be considered in elderly patients with HTN and neural involvement'
• 'Fundoscopy' should be performed in patients with 'severe and/or resistant HTN'
• Elevated BP is associated with increased aortic wall thickness, aortic diameters, and plaque burden in both thoracic and abdominal aorta and 'ultrasound evaluation of abdominal aorta' should be performed in all 'severe long-standing' adult hypertensive patients
• 'Coronary calcium score' may be considered in patients at 'intermediate SCORE risk'
• No current indication for imaging of the kidney to detect subclinical damage
Key messages: Identification of TOD using non-invasive CV imaging-heart
A comprehensive approach to cardiac TOD evaluation in patients with HTN should includes:
• • analysis of 'LV diastolic function and LVFP' (see Figure 4) • 'quantification of GLS' (normal value >20%)
• search for 'myocardial ischaemia' in hypertensive patients with suspected history of coronary artery disease.
adverse outcome and partition values have been proposed for the E/A ratio. 90 The limitation of this parameter relies in the close dependence on age and heart rate that should be accounted for. 92 Tissue Doppler imaging allows estimating LVFP, correlates with wedge pressure, and is associated with CV fatal and non-fatal events. 93, 94 In the ASCOT study, the ratio E/e 0 has been reported to significantly add to predict prognosis beyond clinical risk factors and remained independently associated with prognosis when LV mass and LA size were included in the model. 95 However, this finding needs confirmation in larger studies with sufficient statistical power. In summary, despite the association between several echocardiography-derived parameters of cardiac morphology and function and CV events, LVH currently remains the only established cardiac imaging-derived risk modifier in patients with hypertension.
Cardiovascular system
Vessels BP is the most powerful determinant of carotid IMT and the relationship is apparent from childhood and is related to several BP characteristics, especially systolic BP and pulse pressure. 96 The relationship between carotid IMT and CV risk is continuous, but for clinical purposes, a threshold value of >0.9mm has been adopted by many as the value indicative of increased CV risk. 97, 98 Carotid plaque represents evidence of vascular disease and is strongly predictive of CV events. 6, 95, 99, 100 However, when increased carotid IMT is coexisting, then they seem to add little to each other in predicting CV events or in reclassifying the patient's CV risk. 100 Furthermore, a recent meta-analysis concluded that the addition of IMT to conventional CV risk estimation using the Framingham risk score did not substantially affect reclassification of CV risk 101 or it was associated with little improvement in 10-year risk prediction of first-time myocardial infarction or stroke. 102 Thus, the most useful setting for carotid screening and measurement of IMT in refining CV risk classification may come in patients at low or intermediate risk, 103 or even more in young adults, i.e. <45
years, who are not yet eligible for standard CV risk screening. 104 AS has also been associated with increased CV risk. 6, 105 A metaanalysis of 17 studies reported an almost two-fold increased risk of CV events, CV mortality, and all-cause mortality in subjects with increased aortic PWV demonstrating an higher predictive ability of AS is in subjects with a higher baseline CV risk subjects (coronary artery disease, renal disease, HTN, and diabetes). Coronary artery calcium is recognized as an independent predictor of CV events and mortality, whereas absence of coronary calcium is associated with a very high negative predictive value. 66 Yet the role for risk stratification of uncomplicated HTN is not well defined. In fact, the inclusion of coronary calcium into prediction models mainly improves risk stratification of hypertensive patients at intermediate risk (SCORE risk between 5 and 10%), whereas little value has been demonstrated in patients at low risk. 7, 106 Limited availability, costs, and radiation exposure (±1 mSv) represent substantial limitations to widespread implementation of coronary calcium evaluation in clinical practice.
Kidney, brain, and eye Impaired renal function, assessed by microalbuminuria and GFR, is an independent prognostic marker of future CV events and death in patients with HTN. 107, 108 However, there is no current role for any imaging modality to assess TOD at the kidney level, and, therefore, there are no prognostic implications of imaging-assessed subclinical kidney damage. Subclinical brain injury has been associated with increased risk of stroke, dementia, and cognitive decline. Some studies 109, 110 reported that white matter lesions, frequently associated with long-standing HTN, are significant predictors of stroke and that this relationship is independent of CV risk factors. Moreover, the association between white matter hyperintensities and stroke is also independent of the type and location of lesion and not associated with the occurrence of other major vascular events such as myocardial infarction and vascular death non-stroke related. 109 A systematic review and individual meta-analysis reported that wider retinal venular caliber predicted stroke, while the caliber of retinal arterioles was not associated with stroke. 111 This observation paves the way to future studies designed to evaluate the potential prognostic contribution of non-invasive microvascular bed assessment to risk stratification in hypertensive patients. In summary, several parameters of CV morphology and function are associated with major CV events. To what extent each parameter simply measures different aspects of the same background involvement of CV system is unclear, making it difficult to separate redundant from incremental prognostic information. At this time, the strongest and independent bioassay for modulating CV risk still appears the magnitude of LV mass, but certainly the integration of prognostic information obtainable from TOD evaluation using innovative imaging modalities remains a dynamic evolving aspect of risk stratification in HTN patients.
Key messages: Prognostic implications for imaging-detected TOD-cardiovascular system
• 'Increased IMT, carotid plaques, and coronary calcium' are independent predictors of CV events, but their usefulness to reclassify risk level is limited and mostly valuable in patients at 'intermediate risk'
• 'Subclinical brain injury', assessed by MRI, has been associated with 'increased risk of stroke', dementia and cognitive decline but more studies are needed to assess the prognostic independent role of brain MRI in hypertensive asymptomatic patients 
Effect of anti-hypertensive treatment on TOD and clinical value of TOD modifications
Identification of TOD in the initial workup of patients with HTN impacts on the management of HTN, as it assists the initiation and choice of treatment. 1 In fact, in patients with Grade I HTN, ESH/ESC guidelines recommend, with class of recommendation I, the initiation of treatment if TOD is present, 1 whereas initiation of treatment is recommended with Grade IIa in the absence of TOD. TODs are favourably influenced by the degree of BP reduction per se, and retrospective studies have shown that the treatment-induced regression of some forms of asymptomatic TOD reflects the treatment-induced reduction of CV events. This is particularly true for the regression of LVH (electrocardiographic or echocardiographic) and for the improvement of echocardiographic measures of LV mass and LA size. [112] [113] [114] In patients with LVH, reduction in LV mass closely correlates to BP reduction. However, for comparable reductions in brachial blood pressure, beta-blockers appear less effective than Angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEIs) calcium antagonists, and diuretics. 115 A smaller reduction in central BP and an increase in LV end-diastolic diameter and wall tension secondary to the reduction in heart rate may contribute to the less favourable effects of beta-blockers on LVH. Use of ACEIs or ARBs is generally recommended in patients with TOD, based on the evidence that these classes of drugs improve cardiac and vascular TOD and reduce CV events in high-risk patients. 116 Limited data are available on the differential effects of anti-hypertensive treatment on diastolic dysfunction. The VALIDD trial 117 investigated, on a small series, the effects of valsartan, added to concomitant anti-hypertensive agents, on diastolic function and reported that lowering BP improves diastolic function irrespective of the type of antihypertensive agent used. A substudy of the ASCOT trial 118 described that improved diastolic function was observed in hypertensive patients treated with an amlodipine-based compared with an atenolol-based regimen and that treatment-related differences in diastolic function were independent of BP reduction. However, more evidences are needed to compare the differential effects of anti-hypertensive drugs on diastolic function and to assess whether changes of diastolic function have an independent prognostic impact on hypertensive patients. It has been repeatedly shown that anti-hypertensive therapy result in regression of severe (III and IV) hypertensive retinopathy and that this effect is mainly driven by BP reduction and less influenced by the type of drugs. 119, 120 Prevalence of focal arteriolar narrowing was similar between normotensive (4.6%) and controlled hypertensive subjects (6.5%), whereas its prevalence was more than doubled in treated but uncontrolled (14.5%) and untreated (15.3%) hypertensive patients. Likewise, taken from digitized fundoscopic pictures, the arteriovenous ratio was significantly higher in treated uncontrolled (22.5%) and untreated hypertensive patients (27.2%) than in normotensive subjects (17%). 121 Some data exist that favour the use of ARBs, but evidence is based on small studies. Beyond the established prognostic impact of TOD, the relationship between TOD modifications and prognosis represents a key issue in the management of patients with HTN. In fact, evidence that changes in TOD reflect the modification of CV risk status in individual patients would impact on several aspects of follow-up, including reevaluation programming of diagnostic tests, therapeutic modifications driven by TOD sequential assessment, and costs ( Table 3) . 1 Changes in LV mass and morphology assessed by echocardiography and induced by treatment are related to the effects on risk for CV events. Several studies have demonstrated a reduction in the risk of mortality, stroke, coronary events, or congestive HF among hypertensives who reduce LV mass. 121 However, intra-and inter-operator variability of linear echocardiographic measurements needed to quantify LV mass should be acknowledged, and, to be considered as a true change, LV mass requires a variation of at least 10% or better 20%, which approximately equals 1 SD. In the echocardiographic substudy of the LIFE trial, there was a decrease of about 20% of the primary end point for 1 SD of reduction of LV mass (i.e. 25 g/m 2 ). In that study, it was also shown that LA dimension paralleled the changes in LV mass, suggesting the possible mechanism by which changes in LVH are associated with changing risk of developing atrial fibrillation. Moreover, it has also been shown that changes of LV geometry during treatment may have additional prognostic significance in patients with and without LVH, 122 being persistence or development of concentric hypertrophy the most adverse situation. Worthy of note, in the LIFE study, anti-hypertensive treatment in patients with HTN and electrocardiographic LVH resulted in significant improvement in transmitral flow patterns but was not associated with reduced CV morbidity and mortality; however, normal in-treatment LV filling was strongly associated with a reduced risk for hospitalization for HF. 123 At variance with echocardiography, no cardiac MRI prognostic studies neither changes with treatment assessed with MRI are available in hypertensive patients free of coronary artery disease.
Treatment-induced vascular changes in the carotid artery wall, thickness and plaques, or other territories are less useful for followup, since the changes overtime are minimal and difficult to assess accurately. In fact, there is strong evidence that BP lowering reduces carotid IMT progression, but there is no evidence that regression of IMT is predictive of reduced risk of CV events. 98 Two large metaregression analysis, one in patients enrolled in randomized clinical trials (and therefore subjected to most accurate evaluation of IMT changes) 124 and one in patients enrolled in longitudinal observational studies (PROG-IMT), 125 consistently reported that changes of IMT did not correlate with CV events in patients undergoing anti-hypertensive treatment, although baseline IMT values provided effective risk stratification. 125 Thus, serial evaluation of IMT should not be performed in HTN patients with the aim of monitoring their CV risk over time. Data on the prognostic value of carotid plaque modification induced by therapy are scantier. Interestingly, in a study that followed up for a median of 3.17 years, high-risk patients with evidence of carotid plaques at baseline, changes of total plaque volume but not of IMT at 1 year predicted subsequent major CV events. 126 The prognostic value of changes of hypertensive retinopathy assessed by fundoscopy has been assessed in a 15-year follow-up of 124 subjects, in whom reduction in BP by 30 mmHg was accompanied by a regression of media-to-lumen ratio of subcutaneous small arteries and changes of arteriolar structure were associated with incidence of CV events. 127 Doppler flowmetry of retinal arterioles correlates with media-to-lumen ratio of subcutaneous small arteries, but it is currently unknown whether non-invasively detected changes of microvasculature may predict changes of CV risk status in hypertensive patients.
Gaps in evidence and future perspectives
Technical progress and growing biomedical data have made non-invasive bioimaging an effective approach to the identification and quantification of TOD in untreated and treated hypertensive patients, with a fundamental position in the modern management of this condition as well as of its sequelae. However, several aspects of imaging use remain insufficiently clarified and in need of future studies. First, the clinical value and cost-effectiveness of TOD assessment at different organ levels in a given patient remains undetermined. In fact, although a statistically significant correlation between damage of different organs has been reported, many patients develop, for unknown reasons, substantially different degrees of damage in different organs. Thus, it would be important to determine, via prospective studies, the relationship among bioimaging-assessed cardiac, vascular, and cerebral damage and the value of multi-organ damage assessment for characterization and management of HTN patients. It would be also relevant to prospectively assess treatment-induced BP reductions at which their regression is maximal and normalization possibly achieved. In addition, following the initial disappointing results, studies should also be resumed on the possibility of an accurate bioimaging identification of the tissue components that accompany organ damages such as LVH and large artery wall thickening because the adverse prognostic consequences of either abnormality may importantly depend on the amount of fibrotic tissue growth. Finally, and most importantly, future studies are needed to dispose of a current major criticism, i.e. that evidence of the prognostic value of treatmentinduced changes in TOD is inadequate because based on nonrandomized comparisons of patients with greater or lesser TOD regression, and thus open to the confounding of possible baseline inequalities. This will require outcome-based randomized trials in patients with LVH or other bioimaging-quantifiable damages in whom treatment is guided by their regression rather than on, or in addition to, BP reduction. In addition to improving knowledge on the effects of treatment on prognostically relevant organ damage, the results will provide strong evidence on whether and to what extent organ damage regression increases patient protection and reduces residual risk.
Conclusion
A thorough evaluation of TOD has become a key step in the initial management of patients with HTN. Presence of TOD identifies patients at high CV risk and has relevant impact on therapeutic strategies. Along this process, non-invasive CV imaging is being increasingly used, and innovative imaging techniques are on the way that might further refine risk stratification and provide opportunities to better target therapeutic strategies. Future research is warranted to assess the impact on the outcomes and the cost-effectiveness of noninvasive CV imaging in hypertensive patients.
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